Table 1.
Baseline Patient Characteristics
| Characteristic | Study Group |
P Valuea | |
|---|---|---|---|
| Premask (n = 920) | Mask (n = 911) | ||
| Male sex | 536 (58.3) | 525 (57.6) | .78 |
| Age, y, mean (SD) | 50 (12.7) | 54.7 (12.3) | <.001 |
| Age, y, median (range) | 52 (19–79) | 57 (18–81) | |
| Disease | <.001 | ||
| Leukemia | 237 (25.8) | 186 (20.4) | |
| Lymphoma | 264 (28.7) | 209 (22.9) | |
| PCD | 291 (31.6) | 428 (47) | |
| MDS/MPD | 62 (6.7) | 51 (5.6) | |
| Other | 66 (7.2) | 37 (4.1) | |
| Previous transplant | 15 (1.6) | 12 (1.3) | .58 |
| Type of transplant | <.001 | ||
| Autologous HSCT | 542 (58.9) | 622 (68.3) | |
| Allogeneic HSCT | 378 (41.1) | 289 (31.7) | |
| Myeloablativeb | 196 (51.9) | 172 (59.5) | .05 |
| Alemtuzumabb | 152 (40.2) | 99 (34.3) | .12 |
| Mismatchb | 133 (35.2) | 73 (25.3) | .006 |
| Umbilical cordb | 73 (19.3) | 51 (17.6) | |
| Haploidenticalb | 60 (15.9) | 22 (7.6) | |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: cord, cord blood donor; haploidentical, human leukocyte antigen–haploidentical donor; HSCT, hematopoietic stem cell transplant; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; PCD, plasma cell dyscrasia; SD, standard deviation.
a Wilcoxon rank-sum test for continuous variables and χ2 test for categorical variables.
b Presented as percentage of patients who received allogeneic HSCT.